Daewon Pharmaceutical 19% surge, obesity drug expectations accelerate technology export momentum
Daewon Pharmaceutical 2026year 6month 8day, its stock price rose 19%. Cumulative biotech technology exports in the first half totaled trillion won, while expectations for additional technology exports from Hanmi Pharm grew following its contract with Lilly.13Our cumulative biotech technology exports in the first half totaled trillion won, and expectations for additional technology exports from Hanmi Pharm grew following its contract with Lilly.
Get free 대원제약 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
2026year 6month 8day, Daewon Pharmaceutical's stock price rose 19%. Daewon Pharmaceutical recorded a strong gain that day even as the overall market showed weakness. Media reports cited expectations for its obesity drug as the reason.
Expectations for additional technology exports from Hanmi Pharm this year have grown since its contract with Lilly. As related news emerged, securities firms raised their target prices in some cases. The company is making disclosures related to contracts and clinical trials.
Cumulative biotech technology exports in the first half of this year totaled 13trillion won. This figure included multiple new drug technologies recorded through licensing agreements with global pharmaceutical companies. The industry is watching for the next technology-export leader.
Tirobotics won the Chapek Award in China. The award was reported as recognition of the company’s potential to expand its business related to physical AI. The company disclosed the award.
Samsung C&T’s target price was raised on the assessment that its valuation remains inexpensive despite the rise in its share price. Securities firms released analyses, leading to a change in the target price. The company’s business report and disclosures were cited as references.
On the day, related stocks including Daewon Pharmaceutical, Hanmi Pharmaceutical, Tirobotics, and Samsung C&T drew attention in the market. It was confirmed that market interest was concentrated as major technology export contracts accumulated during the first half of the year. Each company is disclosing details through related filings.